Thousands of rare diseases affect hundreds of millions of people globally, and hope for treatment is on the rise in the form of cell and gene therapies. While only 9 cell and gene therapies are currently FDA-approved in the U.S., that number is soon expected to grow exponentially. With such drastic change on the horizon, the industry needs to be prepared.
In this white paper, Kyle Felmet, Vice President of Specialty Commercialization at Two Labs, discusses the anticipated growth of FDA-approved cell and gene therapies, what that growth means for payers, and the policy changes that will accompany it. Innovation is the name of the game when it comes to these life- and industry-altering therapies, and manufacturers will need expert guidance to keep pace.